A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
Coherus Oncology, Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
City of Hope Medical Center
InSilico Medicine Hong Kong Limited
ALX Oncology Inc.
Genentech, Inc.
Taiho Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Pfizer
Eli Lilly and Company
AstraZeneca
Eli Lilly and Company
China Medical University Hospital
Eli Lilly and Company
University of California, San Diego
University of California, San Francisco
Johannes Gutenberg University Mainz
Eli Lilly and Company
AstraZeneca
M.D. Anderson Cancer Center
UNICANCER
Merck KGaA, Darmstadt, Germany